+142.6%
BKNG vs MRNA
+554.4%
-411.8%
-44.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +5.4% | -5.4% | -0.1% |
| 7D | -9.8% | -1.1% | -8.7% | -9.8% |
| 30D | -17.9% | +126.1% | -144.0% | -21.0% |
| 3M | +6.6% | +190.0% | -183.5% | +1.6% |
| 6M | +1.1% | +157.2% | -156.1% | -3.4% |
| YTD | -18.2% | +388.2% | -406.4% | -23.6% |
| 1Y | -20.2% | +467.0% | -487.2% | -25.9% |
| 3Y | +39.9% | +36.1% | +3.8% | +33.1% |
| 5Y | +93.1% | -68.0% | +161.1% | +81.5% |
| All | +142.6% | +554.4% | -411.8% | +130.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling